Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-25-068536
Filing Date
2025-05-12
Accepted
2025-05-12 07:03:42
Documents
69
Period of Report
2025-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q lxeo-20250331.htm   iXBRL 10-Q 2507132
2 EX-31.1 lxeo-ex31_1.htm EX-31.1 13562
3 EX-31.2 lxeo-ex31_2.htm EX-31.2 13383
4 EX-32.1 lxeo-ex32_1.htm EX-32.1 7624
5 EX-32.2 lxeo-ex32_2.htm EX-32.2 7639
  Complete submission text file 0000950170-25-068536.txt   9545303

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT lxeo-20250331.xsd EX-101.SCH 1504130
72 EXTRACTED XBRL INSTANCE DOCUMENT lxeo-20250331_htm.xml XML 1420649
Mailing Address 345 PARK AVENUE SOUTH FLOOR 6 NEW YORK NY 10010
Business Address 345 PARK AVENUE SOUTH FLOOR 6 NEW YORK NY 10010 (212) 547-9879
Lexeo Therapeutics, Inc. (Filer) CIK: 0001907108 (see all company filings)

EIN.: 854012572 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-41855 | Film No.: 25932543
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)